Evidence map›Paper›PMID 37284756›Full record

ArticleMicrobiology spectrum2023

Seroprevalence of COVID-19 in Oran: Cross-Sectional Study.

Abdessamad Dali-Ali, Dalia Kheira Derkaoui, Mohamed Zina, Asmaa Oukebdane

Abstract read
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Abdessamad Dali-AliUniversity of Oran 1: Ahmed Ben Bella, Faculty of Medicine, Oran, Algeria.ORCID 0000-0003-0600-470X
Dalia Kheira DerkaouiUniversity of Oran 2: Faculty of Sciences, Department of Biology, Oran, Algeria.
Mohamed ZinaPublic Establishment of Proximity Care in Boutlellis, Department of Epidemiology and Preventive Medicine, Boutlellis, Oran, Algeria.
Asmaa OukebdaneCanastel Specialized Hospital, Ophthalmology Department, Oran, Algeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was introduced in Algeria in March 2020. This study aimed to estimate the seroprevalence of SARS-CoV-2 infection in Oran, Algeria, and to identify factors associated with seropositivity. This was a cross-sectional seroprevalence study conducted between 7 and 20 January 2021 across all 26 municipalities in the province of Oran. The study employed a random cluster sampling technique stratified by age and sex to select participants from households, who were then administered a rapid serological test. The overall seroprevalence and specific seroprevalences by municipality were calculated, and the number of COVID-19 cases in Oran was estimated. The correlation between population density and seroprevalence was also examined. Among the participants, 422 (35.6%; 95% confidence interval [CI], 32.9 to 38.4) had a positive serological test for SARS-CoV-2, and eight municipalities had seroprevalence rates above 73%. We found a strong positive correlation between population density and seroprevalence (

Indexed as

COVID-19Antibodies, ViralCross-Sectional StudiesHumansPandemicsSARS-CoV-2Seroepidemiologic StudiesAntibodies, ViralAlgeriaCOVID-19cross-sectional studyOranSARS-CoV-2seroprevalence

Identifiers

PMID37284756
PMCPMC10433985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.